Development of explicit definitions of potentially inappropriate prescriptions for antidiabetic drugs in patients with type 2 diabetes: A multidisciplinary qualitative study.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2024
Historique:
received: 01 03 2024
accepted: 09 08 2024
medline: 27 9 2024
pubmed: 27 9 2024
entrez: 27 9 2024
Statut: epublish

Résumé

The management of type 2 diabetes mellitus patients has changed over the past decade, and a large number of antidiabetic drug treatment options are now available. This complexity poses challenges for healthcare professionals and may result in potentially inappropriate prescriptions of antidiabetic drugs in patients with type 2 diabetes mellitus which can be limited using screening tools. The effectiveness of explicit tools such as lists of potentially inappropriate prescriptions has been widely demonstrated. The aim was to set up nominal groups of healthcare professionals from several disciplines and develop a list of explicit definition of potentially inappropriate prescriptions of antidiabetic drugs. In a qualitative, nominal-groups approach, 30 diabetologists, general practitioners, and pharmacists in France developed explicit definitions of potentially inappropriate prescriptions of antidiabetic drugs in patients with type 2 diabetes mellitus. A nominal group technique is a structured method that encourages all the participants to contribute and makes it easier to reach an agreement quickly. Each meeting lasted for two hours. The three nominal groups comprised 14 pharmacists, 10 diabetologists, and 6 general practitioners and generated 89 explicit definitions. These definitions were subsequently merged and validated by the steering committee and nominal group participants, resulting in 38 validated explicit definitions of potentially inappropriate prescriptions of antidiabetic drugs. The definitions encompassed four contexts: (i) the temporary discontinuation of a medication during acute illness (n = 9; 24%), (ii) dose level adjustments (n = 23; 60%), (iii) inappropriate treatment initiation (n = 3; 8%), and (iv) the need for further monitoring in the management of type 2 diabetes mellitus (n = 3; 8%). The results of our qualitative study show that it is possible to develop a specific list of explicit definitions of potentially inappropriate prescriptions of antidiabetic drugs in patients with type 2 diabetes mellitus by gathering the opinions of healthcare professionals caring for these patients. This list of 38 explicit definitions necessitates additional confirmation by expert consensus before use in clinical practice.

Identifiants

pubmed: 39331645
doi: 10.1371/journal.pone.0309290
pii: PONE-D-24-07859
doi:

Substances chimiques

Hypoglycemic Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0309290

Informations de copyright

Copyright: © 2024 Gerard et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Auteurs

Erwin Gerard (E)

CHU Lille, ULR 2694 - METRICS: Evaluation des Technologies de Santé et des Pratiques Médicales, Univ. Lille, Lille, France.

Paul Quindroit (P)

CHU Lille, ULR 2694 - METRICS: Evaluation des Technologies de Santé et des Pratiques Médicales, Univ. Lille, Lille, France.

Matthieu Calafiore (M)

CHU Lille, ULR 2694 - METRICS: Evaluation des Technologies de Santé et des Pratiques Médicales, Univ. Lille, Lille, France.
Department of General Practice, University of Lille, Lille, Lille, France.

Jan Baran (J)

Department of General Practice, University of Lille, Lille, Lille, France.

Sophie Gautier (S)

CHU de Lille, UMR-S1172, Center for Pharmacovigilance, Univ. Lille, Lille, France.

Stéphanie Genay (S)

CHU Lille, Institut de Pharmacie, Lille, France.
CHU Lille, ULR 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées, Univ. Lille, Lille, France.

Bertrand Decaudin (B)

CHU Lille, Institut de Pharmacie, Lille, France.
CHU Lille, ULR 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées, Univ. Lille, Lille, France.

Madleen Lemaitre (M)

CHU Lille, ULR 2694 - METRICS: Evaluation des Technologies de Santé et des Pratiques Médicales, Univ. Lille, Lille, France.
Department of Diabetology, CHU Lille, Endocrinology, Metabolism and Nutrition, Lille University Hospital, Lille, France.

Anne Vambergue (A)

Department of Diabetology, CHU Lille, Endocrinology, Metabolism and Nutrition, Lille University Hospital, Lille, France.
European Genomic Institute for Diabetes, University School of Medicine, Lille, France.

Jean-Baptiste Beuscart (JB)

CHU Lille, ULR 2694 - METRICS: Evaluation des Technologies de Santé et des Pratiques Médicales, Univ. Lille, Lille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH